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This review summarizes recent information on the effects of 
immunomodulatory cytokines on human melanoma cells. 
The action of interferon (IFN}-alpha, -beta, and -gamma has 
been extensively examined in melanoma and melanocyte 
cultures in vitro, and increasing information on the action of 
other cytokines is now available. All IFNs revealed a dose­
dependent antiproliferative effect on melanoma cells with 
the highest growth inhibition caused by IFN-beta. Prolifera­
tion was also inhibited by interleukin (IL) 1-alpha and -beta, 
and tumor necrosis factor (TNF}-alpha. For IL-4, both 
growth-stimulatory and -inhibitory properties have been re­
ported. Cellular differentiation in terms of melanin synthe­
sis, formation of dendrite like structures, and antigenic 
changes was not affected by IFN-alpha or -beta. IFN­
gamma, however, induced a more dedifferentiated and bio-
R ecombinant technology has allowed large scale cyto­kine production and thereby provided the facilities for new cancer treatment concepts. The finding of direct antiproliferative effects of different interferons (IFNs) on melanoma cells in vitro focused the attention on 
these substances as possible antitumor agents for therapeutic pur­
poses [1,2). Additionally, the involvement ofIFNs in the regulation 
of the immune system and in cellular differentiation has been de­
scribed [3-5). These different mechanisms of action may possibly 
contribute to the antitumoral activity ofIFNs, which are used today 
for systemic treatment of metastatic melanoma and are combined 
for this purpose with different cytokines and cytotoxic drugs [6). 
Several new cytokines have been detected and characterized in the 
last years and some of their effects on melanoma cells have been 
investigated recently (Table I). Interleukin (IL) 1, IL-4, tumor ne­
crosis factor (TNF) alpha, and transforming growth factor (TGF) 
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Abbreviations: 
CD: cluster of differentiation 
GD2, GM2: ganglioside 02, M2 
HLA: histocompatibility antigen 
HMW-MAA: high molecular weight-MAA 
ICAM-I: intercellular adhesion molecule-I 
IFN(s): interferon(s) 
IL(s): interleukin(s) 
LFA-3: leukocyte function antigen-3 
MAA: melanoma associated antigen 
MoAb(s): monoclonal antibody(ies) 
NK: natural killer 
TGF-beta: transfOrming growth factor-beta 
TIL: tumor infiltrating lymphocytes 
TNF-alpha: tumor necrosis factor-alpha 
VLA: very late antigen 
logically more aggressive phenotype of melanoma cells. His­
tocompatibility antigen (HLA) class I molecules were found 
upregulated by all IFN s and by TNF-alpha, associated with a 
marked increase of melanoma cell lysis by tumor infiltrating 
lymphocytes in vitro. HLA class II molecules were de novo 
expressed or enhanced by IFN-gamma and TNF-alpha. The 
adhesion molecules ICAM-1, LFA-3, and VLA-2 were up­
regulated by IFN-gamma, TNF-alpha, and IL-1-beta, 
whereas melanoma-associated antigens were hardly affected 
by cytokines. It seems that both antiproliferative and 
immunomodulatory effects may contribute to the antitu­
moral activity of cytokines in vivo. In vivo application of cyto­
kines as well as combinations with cytotoxic drugs, therefore, 
may be promising for future treatment strategies. ] Invest 
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beta-1 inhibited melanoma cell proliferation in vitro [7 -13). IL-6 
showed growth-stimulatory properties in murine melanoma cells 
[14). The present knowledge on cytokine effects in benign and 
malignant melanocytes is mainly based on investigations in vitro. So 
far, there are only few systematic investigations on the different 
effects of single cytokines on melanoma cells. This review sum­
marizes the available data on IFNs and other cytokines on the pro­
liferation, cellular differentiation, the antigenic profile of mela­
noma cells, and their indirect effects via immune responses of the 
host. 
DIRECT ANTIP ROLIFERATIVE EFFECTS 
Interferons The role of IFNs as growth inhibitory compounds 
for human melanoma cells in vitro is well established. Czamiecki et 
al described synergistic antiviral and antiproliferative effects of re­
combinant human IFN-alpha, -beta and -gamma [2). Both type I 
and II IFN are capable of inhibiting the proliferation of fresh and 
long-term cultured melanoma cells either in soft agar or monolayer 
systems [1,2,15,16). Contradictory results have been reported on 
which type ofIFN is most effective with respect to antiviral units or 
molar concentrations. Although some investigators report type II 
IFN-garnma as the most potent agent [17), we and others found a 
clearly higher efficiency oflFN-beta compared to both IFN-alpha 
and IFN-gamma to inhibit the proliferation of established mela­
noma cell lines (Fig 1) [5,16). These effects were predominantly 
cytostatic. Removal of IFN from the culture medium resulted in a 
rapid onset of proliferation (Fig 2). The combination of type I IFNs, 
IFN-alpha, and IFN-beta, which bind to the same receptor, resulted 
in subadditive antiproliferative effects, possibly due to decreased 
binding ofIFN-beta to type I IFN -receptor [16). On the other hand, 
combination of type I and II IFN led to a strong synergistic action of 
both compounds [16). Comparative studies performed on normal 
human melanocytes showed a strong antiproliferative activity of 
IFN-beta and little or no action oflFN-alpha or -gamma [18). 
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Table I. Cytokines Investigated for Their Effects on Melanoma Cells 
Chromosomal 
Molecules Synonyms Localization 
IFN-a Lymphoblast 9p13-21 
IFN 
IFN-P Fibroblast 9p22 
IFN 
IFN-}, Immune 12 
IFN 
TNF-a Cachectin 6p23;q12 
IL-l a Hemopoietin-l 2q14 
IL-l P 2q14 
IL-4 B-cell stimulatory factor 5q 
IL-6 IFN-82 7q 
TGF-p-l 19q13.1 
Tumor Necrosis Factor-Alpha No conclusive information 
exists on the capacity of TNF-alpha to inhibit the proliferation of 
cultured melanoma cells [9,13]. Apparently, only a subgroup of 
melanoma cell lines responded to TNF-alpha, and TNF-alpha, 
having cytotoxic rather than cytostatic effects, may select in vitro for 
melanoma cells with enhanced malignancy [13]. In animal models 
TNF-alpha revealed a significant antitumoral activity against malig­
nant melanoma [19]. Additional studies performed on melanocyte 
cultures by Swope et al showed that TNF-alpha is able to inhibit 
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157 17 [9,11,13,48] 
269;152 31;17 [8,26] 
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212 24 [14,20] 
112 12.5 [7,22,24] 
both 3H thymidine incorporation into the DNA and cell prolifera­
tion [20]. 
Transforming Growth Factor-Beta Melanoma cells can pro­
duce TGF-beta, a potent immunoregulatory mediator [21,22]. Al­
though TGF-beta stimulates proliferation of murine melanoma 
cells [23], various reports ascribe a growth-inhibitory role for this 
molecule in the human system [7,22,24]. On cultured melanocytes, 
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Figure 1. Dose-dependent growth inhibition of melanoma cell lines SKMel-28 and StML-11 by rIFN-alpha-2a, nIFN-beta, and rIFN-gamma. The 
IFN-doses are expressed in antiviral units (internationally defined units for IFN-alpha and IFN-beta, whereas no international standard exists for 
IFN-gamma) (a,b) and additionally in picomolar concentrations (c,d) [16]. 
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Figure 2. Reve!Sibility of growth inhibition of melanoma cell lines 
SKMel-28 after a 2-day treatment with rIFN-alpha-2a, nIFN-beta, and 
rIFN-gamma (100 U/ml) [16]. 
TGF-beta prevents cell replication by arresting cells in the GO/G1 
phase [25]. 
Interleukius Scant information exists on IL-l action on pigment 
cells. Most melanoma cell lines are resistant to IL-l. IL-lalpha sen­
sitive cell lines have been described, such as A375 [8,26]. Mortarini 
et al found three of nine melanoma cell lines to respond to IL-l beta 
[9]. The same authors found inhibition of melanoma cell prolifera­
tion by IL-4 in three of nine cultures tested; however, a slight 
stimulatory effect was observed in two others. Hoon et al also re­
ported that incubation of human melanoma cells in vitro with IL-4 
resulted in significant inhibition of proliferation [10]. The effects of 
other cytokines on melanoma cells are unknown so far; there are 
only two reports on the growth stimulation of murine melanoma 
cells by IL-6 [14], and of growth inhibition in melanocyte cultures 
[20J. 
The mode of antiproliferative action of cytokines such as IFNs 
seems to be cytostatic without clear cytotoxic effects. The growth 
control is associated with a decreased probability of the cytokine­
treated cells to enter the cell cycle and an increasing portion remain­
ing in the Go phase. Possibly, this effect is mediated by increasing 
levels of (2'-5') oligoadenylate synthetase [27J. Combined cytokine 
treatment of melanoma cells revealed synergistic antiproliferative 
effects with IFN-�amma and TNF-alpha or IFN-alpha and IFN­
gamma [16,28,29J. These synergistic dfects are probably mediated 
through the induction of cytokine receptors on melanoma cells 
[29J. 
CELLULAR DIFFERENTIATION 
The term differentiation has been used to describe processes leading 
to the expression of phenotypic properties characteristic for func­
tionally mature cells in vivo. Tnere appears to be an inverse relation­
ship between the expression of differentiation and malignancy asso­
ciated properties, even to the extent that induction of differentiation 
has been proposed as a model for cancer treatment [30J. IFNs are 
known to induce cellular differentiation in different hematologic 
malignancies [31 J and, therefore, the investigation of their differen­
tiating effects in other malignant tissues including melanoma 
seemed promising. 
Mature melanocytes and melanotic melanoma cells possess the 
ability
m
t�;lnthesize melanin from tyrosine. This process is regu­
lated . y by a single enzyme, tyrosinase, which catalyses three 
separate reactions during the conversion process [32J. Therefore, 
synthesis of melanin as well as the activity of tyrosinase are regarded 
as highly indicative measures for the expression of differentiated 
properties in melanocytic cells [5,16,33J. Additionally, melanocytes 
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Table U. AntiproJiferative Effects of Cytokines on Melanoma 
CelIs and Melanocytes· 
Melanoma 
Cells References Melanocytes References 
IFN-a ++ [1,2,5,6,15,17] 0/+ [18] 
IFN-P +++ [1,2,5,6,15,17] +++ [18] 
IFN-y ++ [2,6,15,17] 0/+ [18,20] 
TNF-a 0/+ [9,10,11,12,13] ++ [20] 
IL-la 0/+ [8,26] + [20] 
IL-IP 0/+ [9] NO 
IL-4 */+ [9,10] NO 
IL-6 * [14] 0/+ [20] 
TGF-Pl */+ [22,23,24] +++ [25] 
• Crosses indic:ate inhibition of cellular proliferation as follows: +, little; ++, 
medium; +++, high. * growth stimulation; and 0, no effect; ND, not done. 
deliver melanin to keratinocytes via long dendrites in vivo. The 
formation of dendrites can also be observed in cell culture, and 
dendritelike structure formation may be interpreted as a sign indi­
cating cellular differentiation in melanoma cells [16,33J. Further­
more, the antigenic phenotype is linked to melanocyte maturation 
and cellular differentiation and certain antibody-defined mela­
noma-associated molecules were revealed to be useful markers of 
melanocytic differentiation [4,16,34]. 
Interferon-Alpha and -Beta Induction of cellular differentia­
tion has been investigated in both murine and human melanoma 
cells. IFNs are so far the only cytokines that were broadly examined 
with respect to their differentiating effects on melanoma cells. 
Fisher et al found after the application of IFN -alpha and -beta in 
both murine and human melanoma cells that there was no increase 
in melanin production or in dendritelike structure formation [5,35J. 
Concerning IFN-alfha and -beta, we confirmed these results in 
different human eel lines [16J; no significant changes of cellular 
morphology, melanin synthesis, or expression of differentiation 
markers were detected. Interestingly, a combination of type I IFNs 
with an inducer of melanoma cell differentiation, such as mezerein, 
proved to stimulate differentiation and to inhibit cell growth to a 
significantly higher degree than mezerein as a single agent [5J. 
Interferon-Gamma On the contrary, application of IFN­
gamma significantly reduced dendritelike structure formation and 
inhibited melanin synthesis JI6]. Furthermore, IFN-gamma en­hanced progression-associate melanoma markers like the intercel­
lular adhesion molecule-l (ICAM-l) and very late antigen (VLA)-2 
molecules rmonoclonal antibody (MoAb) A.1.43J [16J. Therefore, 
it seemed that a dedifferentiated, biologically more aggressive phe­
notype of melanoma cells had resulted after treatment with IFN­
gamma. 
MODULATION OF CELL SURFACE 
ANTIGEN EXPRESSION 
Different classes of antibody-defined melanoma antigens are suscep­
tible to modulation by various cytokines in vitro. Among these, three 
classes of antigens could be relevant in predicting the interaction of 
individual tumor cells with immune cells, thus being determinants 
of antitumor response: (1) HLA class I and II antigens, (2) lympho­
cyte adhesion molecules, and (3) surface antigens preferentially ex­
pressed by malignant melanoma cells. 
Interferon-Alpha and -Beta Several reports have shown that 
type I IFN's (IFN-alpha and IFN-beta) enhance the expression of 
HLA class I on melanoma cells [3,16,36,37J. On the contrary, ex­
pression ofHLA class II antigens was either not induced by IFN-al­
pha or -beta [4,16,37J or only moderately enhanced, especially after 
IFN-beta treatment [3,36,38]. In contrast to IFN-gamma, increased 
expression of histocompatibility products occurs by a process not 
requiring de novo protein synthesis [39J. In addition to HLA mole-
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Tablem. Modulation of Melanoma Antigens by Cytokines in Vitro' 
HLA-I HLA-II ICAM-l LFA-3 VLA-2 G03 HMW-MAA 
IFN-a ++ 0/+ 0 0 0 0 0/+ 
IFN-P +++ 0/+ 0 0 0 0 0/+ 
IFN-)I ++ +++ +++ + + 0 
TFN-a ++ + ++ + + 0 0/+ 
11-1 NO 0 ++ + NO 0 0 
11-4 ++ ++ NO NO NO 0 0 
• Crosses indicate upregulation of antigens as follows: +, little; ++, medium; +++, high; -, downregulation of antigen; 0, no effect; NO, not done. 
cules, a number of other antigens preferentially expressed on malig­
nant melanoma cells and designated as melanoma-associated anti­
gens (MAA), can be modulated by IFNs. Giacomini et al found an 
increased shedding of the high molecular weight (HMW)-MAA by 
type I IFN and an enhanced expression and shedding of three other 
100-115 kD MAAs [3]. 
Interferon-Gamma IFN-garnma is a potent inducer of HLA 
class I antigens on melanoma cells in vitro [4,36-38,40], similar to 
type I IFN. In addition, IFN -gamma is able to induce strong expres­
sion of HLA-DR antigens even in class II negative melanoma cell 
lines [4,36-38,40]. The capacity of IFN-gamma to induce HLA II 
antigens is much higher in comparison to type I IFN (up to 3 times 
for HLA-DR/DP antigens and up to 10 times for HLA-DQ [36]). 
HLA-DR is more susceptible to upregulation by IFN-gamma than 
HLA-DQ or -DP antigens [16,38,41,42]. Different mechanisms 
are seemingly responsible for the modulation ofHLA-DR on mela­
noma cells than for the mediation of antiproliferative effects or for 
the upregulation of HLA-I by IFN-gamma, as shown in experi­
ments using IFN-gamma resistant melanoma cell lines [43]. Specific 
modulation by IFN-gamma could be shown for the ICAM-l by 
several investigators using monoclonal MoAbs directed against dif­
ferent epitopes of this adhesion molecule, such as MoAbs CL203, 
CL207, and 84HI0 [16,44]. For this process de novo RNA and pro­
tein synthesis are required [44]. Regarding the modulation of MAA 
expression by IFN-gamma, Houghton et al [4] and Herlyn et al [40] 
found no modulation of MAA by either type I or type II IFN in 
contrast to HLA. On the other hand, IFN-garnma reduced the 
synthesis of both HMW -MAA and of 100-kD MAA [45]. Guiffre et 
al reported on a novel MAA inducible by gamma-IFN, a 33 to 
38 kD glycoprotein expressed on melanoma cells [34]. Expression 
of p97 has been found enhanced by both type I IFN-alpha and type 
II IFN-gamma [46]' We found that IFN-gamma additionally in­
duced the expression of the progression marker A.1.43, which was 
recently shown to bind to the VLA-2 integrin [47]. On cultured 
melanocytes, changes of the antigenic profile similar to those de­
scribed for melanoma cells have been induced by type I and II IFN 
[18]. 
Tumor Necrosis Factor-Alpha TNF-alpha has been shown to 
increase the expression of both HLA-class I and class II DR antigens 
as well as of ICAM-l on melanoma cells, although it is less potent 
than IFN-gamma [9,10,48]. Maio et al reported that regulation of 
HLA-DR expression involved both transcriptional and post-tran­
scriptional mechanisms [48]. TNF-alpha did not influence expres­
sion of HMW-MAA [48], but significantly enhanced ganglioside 
D2 ( GD2) expression [10]. Also, it increased the expression of the 
progression marker VLA-2 antigen and reduced the expression of 
the early marker K.1.2 [13]. 
Interleukins The effects ofILs on the immunophenotype of mel­
anoma cells in vitro have been far less well investigated. Mortarini et 
al described borderline changes ofHLA-DR and of MAA expression 
on various melanoma cell lines incubated with IL-l beta, or IL-4 [9]. 
In those experiments, a hierarchy in cytokine effects could be 
shown, with IFN-gamma being the most potent immunoregulatory 
agent, followed by TNF-alpha. Similar results with IL-4 were re­
ported by Hoon et ai, showing the induction ofHLA-1 and II anti-
gens and an elevation of the GM3/GD3 ratio and enhancement of 
GD2 by IL-4 [10]. 
INDIRECT EFFECTS VIA THE IMMUNE 
RESPONSE OF THE HOST 
Interferon-Alpha and -Beta IFN-alpha is obviously in a posi­
tion to augment the natural killer ( NK) cell activity in vitro and in 
vivo [49,50]. Interestingly, an initial and transient decline in blood 
NK cell activity during the first hours after IFN application has 
been described that seems to be mediated by suppressor monocytes 
[51]. An increase of NK activity against melanoma cell lines was 
only found during the first treatment cycle in melanoma patients, 
but in subsequent treatment cycles NK activity tended to decrease 
[52]. Therefore, it remains controversial whether the moderate stim­
ulation of NK activity by type I IFN s may contribute to any relevant 
antitumoral activity. Recently, the antitumor/antimetastatic effects 
of immune cells and their modulation by IFNs has been studied in a 
murine animal model. Depletion of NK cells, alone or in combina­
tion with T cells, eliminated the protective effect ofIFN treatment; 
by depletion of CD4-cells alone the protective effect was also elimi­
nated. These results demonstrate the importance of the interaction 
of different components of the immune systems and their activation 
by IFNs [53]. 
Interferon-Gamma The enhancement of HLA class I antigens 
by IFN-gamma correlated with decreased target susceptibility to 
lysis by NK cells, whereas the ability of tumor infiltrating lympho­
cytes (TIL) to lyse the cultured tumor target was markedly increased 
by pre-incubation of the targets with IFN-gamma [54]. It has been 
proved in an animal model that the expression of HLA class I anti­
gens is essential for TIL activity [55]. IFN-gamma was shown in a 
murine model to activate macrophages to kill melanoma rumor 
targets [56]. IFN-gamma increases the expression of ICAM-l on 
melanoma cells and the expression of this antigen was found to be 
associated with an increase of melanoma cell vulnerability to mono­
cyte-mediated killing [57]. 
Tumor Necrosis Factor-Alpha TNF-alpha enhances HLA 
class I antigen expression and increases the expression ofl CAM-l 
[54,57]. Pre-incubation of melanoma cells with TNF-alpha, there­
fore, induces resistance against NK-cell lysis, increases lysis by TIL 
and also the sensitivity of these cells to monocyte-mediated killing 
[54,57]. 
Melanoma cells are not only sensitive targets to different cyto­
k4J,es, but they possess the capacity to produce cytokines them­
·selves. IL-l, IL-6, and TGF-beta have been detected to be secreted 
by cultured melanoma cells [58-61]. Furthermore, additional 
growth factors are produced by melanoma cells [62]. The influence 
of exogenous cytokines on the autocrine production of cytokines by 
melanoma cells has not yet been examined. 
FUTURE PERSPECTIVES OF CYTOKINE 
TREATMENT IN MELANOMA 
Mainly the IFN s have been examined in melanoma treatment. High 
local tissue concentrations after intralesional application into metas­
tases of both IFN-alpha and IFN-beta led to a regression of more 
than 50% of the metastases [63,64]. Also, after systemic application 
of IFN -alpha and IFN -beta in over 500 patients, the mean response 
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rates were between 10% and 15% for the different agents [6,65]. In 
light of in vitro results, it appeared promising to study the effective­
ness of IFNs in combination with cytostatic drugs [16]. The results 
of more than 15 clinical trials have already been published and a 
number of other clinical studies are under way. Results of in vitro 
trials showed that type I IFNs may produce antagonistic effects 
combined with some agents (e.g., cisplatin) and synergistic effects 
when combined with others (e.g., vindesine and BCNU) [6,66]. 
Clinical trials with combined IFN s and cytostatic drug therapy were 
started a few years ago and have yielded promising initial results. 
Various investigators reported a response rate of 25% to 30% with a 
combination of dacarbazine and IFN-alpha [6]. So far, similar re­
sponse rates have only been achieved by combining three to four 
cyostatic agents that involved a much higher toxicity [65]. Based on 
the published results, this therapeutic concept can be considered 
safe in practice and seems to be a useful alternative to polychemo­
therapy. 
Recent reports on multidrug regimens including IFN-alpha re­
vealed surprisingly high overall response rates of greater than 50%, 
which belong to the highest response rates ever described for meta­
static melanoma [6]. Interestingly, the addition ofIL-2 to combina­
tion schedules seemed to augment the response rates further. IL-2 
has no direct effects on melanoma cells in vitro, but it transforms 
precursor lymphocytes into lymphokine activated killer cells and 
stimulates the capacity to lyse tumor cells resistant to NK cells. 
Improvement of response rates by the addition of IL-2 is in agree­
ment with the results of various IL-2 trials in disseminated mela­
noma in which the best responses were obtained by combining IL-2 
and IFN-alpha [67]. Possibly, future therapeutic schedules for meta­
static melanoma will include combinations of cytotoxic drugs with 
cytokines showing antiproliferative capacity or enhancement of im­
munologic mechanisms against melanoma cells. 
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